Share on LinkedInShare on LinkedIn

ARTICLE · 04 DECEMBER 2019

FDA Explains Current Thinking On CBD And Issues Targeted Warning Letters

Akin
Akin
Contributor
Akin

Akin

Akin is a global law firm with more than 1,100 lawyers and advisors who pride themselves on...

View firm profile
Explore more from Akin

On November 25, the Food and Drug Administration (FDA) issued 15 warning letters to companies selling products ...

United StatesFood, Drugs, Healthcare, Life Sciences

On November 25, the Food and Drug Administration (FDA) issued 15 warning letters to companies selling products containing hemp-derived cannabidiol (CBD) and released a summary of its approach to the regulation of CBD products.

FDA issued these recent warning letters to companies marketing CBD products with health benefit claims, including claims that the product will treat conditions such as cancer, anxiety, pain and inflammation. Keeping in line with prior warning letters FDA has issued regarding CBD, FDA asserts that these claims render the products unapproved new drugs in violation of the Federal Food, Drug and Cosmetic Act (FDCA).

Further, the warning letters discuss FDA’s view that the FDCA prohibits the sale of food or dietary supplements containing CBD. In announcing the warning letters, FDA stated that it cannot conclude that CBD is generally recognized as safe (GRAS) among qualified experts for use in human or animal food. The warning letters also focus on

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from